Drug giant Roche blew away the competition and moved quickly with its $8.3 billion bid for InterMune Inc. Yet Brisbane-based InterMune (NASDAQ: ITMN) still was able to get more than Roche’s original bid, according to a Securities and Exchange Commission document filed Friday. Roche, the parent company of South San Francisco’s Genentech Inc., on Friday started offering InterMune stockholders $74 per share.